A detailed history of Wells Fargo & Company transactions in Prothena Corp Public LTD CO stock. As of the latest transaction made, Wells Fargo & Company holds 60,711 shares of PRTA stock, worth $1.06 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
60,711
Previous 51,049 18.93%
Holding current value
$1.06 Million
Previous $1.26 Million 0.87%
% of portfolio
0.0%
Previous 0.0%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$19.54 - $26.15 $188,795 - $252,661
9,662 Added 18.93%
60,711 $1.25 Million
Q1 2024

May 10, 2024

BUY
$24.75 - $40.66 $125,705 - $206,512
5,079 Added 11.05%
51,049 $1.26 Million
Q4 2023

Feb 09, 2024

SELL
$32.31 - $52.32 $338,867 - $548,732
-10,488 Reduced 18.58%
45,970 $1.67 Million
Q3 2023

Nov 13, 2023

BUY
$47.3 - $70.6 $33,299 - $49,702
704 Added 1.26%
56,458 $2.72 Million
Q2 2023

Aug 15, 2023

BUY
$48.26 - $78.59 $407,024 - $662,828
8,434 Added 17.82%
55,754 $3.81 Million
Q1 2023

May 12, 2023

BUY
$46.97 - $58.27 $1.72 Million - $2.14 Million
36,655 Added 343.69%
47,320 $2.29 Million
Q4 2022

Feb 13, 2023

SELL
$52.05 - $65.0 $95,459 - $119,210
-1,834 Reduced 14.67%
10,665 $642,000
Q3 2022

Nov 14, 2022

BUY
$25.16 - $60.63 $6,742 - $16,248
268 Added 2.19%
12,499 $758,000
Q2 2022

Aug 12, 2022

SELL
$22.73 - $39.98 $342,131 - $601,778
-15,052 Reduced 55.17%
12,231 $332,000
Q1 2022

May 16, 2022

SELL
$30.27 - $49.22 $330,094 - $536,744
-10,905 Reduced 28.56%
27,283 $997,000
Q4 2021

Feb 14, 2022

SELL
$42.11 - $73.26 $764,001 - $1.33 Million
-18,143 Reduced 32.21%
38,188 $1.89 Million
Q3 2021

Nov 15, 2021

BUY
$48.2 - $78.89 $1.99 Million - $3.25 Million
41,215 Added 272.66%
56,331 $4.01 Million
Q2 2021

Aug 16, 2021

SELL
$21.63 - $57.65 $170,076 - $453,301
-7,863 Reduced 34.22%
15,116 $777,000
Q1 2021

May 13, 2021

SELL
$11.0 - $28.24 $272,404 - $699,335
-24,764 Reduced 51.87%
22,979 $576,000
Q4 2020

Feb 09, 2021

BUY
$10.12 - $13.94 $114,922 - $158,302
11,356 Added 31.21%
47,743 $573,000
Q3 2020

Nov 05, 2020

SELL
$9.93 - $13.47 $76,679 - $104,015
-7,722 Reduced 17.51%
36,387 $364,000
Q2 2020

Aug 13, 2020

BUY
$9.56 - $12.51 $79,539 - $104,083
8,320 Added 23.25%
44,109 $461,000
Q1 2020

May 14, 2020

BUY
$7.54 - $15.77 $269,849 - $564,392
35,789 New
35,789 $382,000

Others Institutions Holding PRTA

About PROTHENA CORP PUBLIC LTD CO


  • Ticker PRTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,922,800
  • Market Cap $821M
  • Description
  • Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...
More about PRTA
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.